408 related articles for article (PubMed ID: 25400031)
21. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
22. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
24. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
26. [Biomarkers and anti-EGFR therapies for KRAS wild-type tumors in metastatic colorectal cancer patients].
Díaz-Rubio García E
An R Acad Nac Med (Madr); 2009; 126(2):243-57; discussion 258-62. PubMed ID: 20432670
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
[TBL] [Abstract][Full Text] [Related]
28. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
29. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
Peeters M; Price T; Van Laethem JL
Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
[TBL] [Abstract][Full Text] [Related]
30. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
[TBL] [Abstract][Full Text] [Related]
32. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
33. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
34. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
Baynes RD; Gansert J
Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
[TBL] [Abstract][Full Text] [Related]
35. Panitumumab in metastatic colorectal cancer.
Hocking CM; Townsend AR; Price TJ
Expert Rev Anticancer Ther; 2013 Jul; 13(7):781-93. PubMed ID: 23802848
[TBL] [Abstract][Full Text] [Related]
36. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
Cohenuram M; Saif MW
Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
[TBL] [Abstract][Full Text] [Related]
37. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
39. Integration of panitumumab into the treatment of colorectal cancer.
Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
[TBL] [Abstract][Full Text] [Related]
40. [Panitumumab-treatment of metastatic colorectal cancer].
Pikó B
Magy Onkol; 2009 Jun; 53(2):135-42. PubMed ID: 19581179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
